Los Angeles Capital Management LLC Acquires Shares of 23,433 Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Los Angeles Capital Management LLC bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 23,433 shares of the biotechnology company’s stock, valued at approximately $544,000. Los Angeles Capital Management LLC owned approximately 0.09% of Arcturus Therapeutics as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in ARCT. Russell Investments Group Ltd. acquired a new stake in shares of Arcturus Therapeutics during the 1st quarter worth $40,000. nVerses Capital LLC acquired a new stake in Arcturus Therapeutics during the third quarter worth about $42,000. Quest Partners LLC increased its holdings in Arcturus Therapeutics by 3,283.5% in the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 3,579 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 2,038 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Arcturus Therapeutics during the 2nd quarter worth approximately $142,000. Institutional investors own 94.54% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on ARCT. HC Wainwright restated a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Friday, November 8th. Leerink Partners initiated coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They issued an “outperform” rating and a $70.00 price objective on the stock. Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $71.40.

Arcturus Therapeutics Price Performance

Shares of NASDAQ ARCT opened at $16.02 on Friday. The company has a 50 day simple moving average of $20.54 and a 200 day simple moving average of $23.97. Arcturus Therapeutics Holdings Inc. has a 1 year low of $14.93 and a 1 year high of $45.00. The firm has a market cap of $433.93 million, a PE ratio of -7.22 and a beta of 2.64.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. The company had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same quarter in the previous year, the business earned ($0.61) earnings per share. As a group, research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.31 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the transaction, the chief operating officer now directly owns 435,334 shares of the company’s stock, valued at $9,037,533.84. The trade was a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.30% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.